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Imaging techniques currently used for MS diagnosis and follow-up are not able to differentiate and separately measure each of the neuropathological components which are thought to play a major role in the pathophysiology of the disease, including adaptive and innate immune cell inflammation, myelin content changes (demyelination and remyelination) and neuronal damage. Several advanced quantitative magnetic resonance imaging (MRI) techniques have proven to be extremely sensitive for detecting microstructural changes affecting both lesions and normalappearing tissues in patients with MS. However, since similar changes in the physical properties of tissues detected by MRI can result from multiple pathological processes indistinguishable from each other, the interpretation of imaging data acquired with magnetic resonance (MR)-based sequences remains challenged by an intrinsic suboptimal specificity.
Being based on the use of radiolabelled compounds selectively binding to specific biological targets, positron emission tomography (PET) offers the highest possible specificity to explore the mechanisms underlying brain pathological changes in MS. PET has a lower resolution and is more expensive than MRI, and its wide application is limited by the use of radiations and the requirement of multidisciplinary expert teams for data acquisition and processing. However, the exceptional specificity of this technique offers the unique opportunity to precisely quantify in vivo each of the neuropathological components involved in the pathophysiology of MS and to get as close as possible to the biology of the disease.
To date, the translocator protein (TSPO) has been the most widely used target for innate immune cells imaging with PET. It is a macromolecular complex localized in the outer mitochondrial membrane, whose expression is mainly, but not exclusively, driven by innate immune cell activation. The first compound applied to explore TSPO expression in MS was the 11 C-PK11195. Pilot 11 C-PK11195 PET studies allowed to detect an increased tracer uptake in patients with all forms of MS, both inside lesions and in normalappearing tissues. 1,2 As 11 C-PK11195 is characterized by several technical limitations, a large number of second-generation TSPO tracers have subsequently been developed, allowing to describe more accurately the neuro-inflammatory component of brain pathology. Second-generation TSPO tracers have been employed to confirm a diffuse activation of innate immune cells both in the normal-appearing white matter and in cortical regions 3 and to demonstrate that innate immune cell activation predicts white matter lesion enlargement and brain atrophy after 12 months. 4 Second-generation TSPO ligands have also allowed to revisit the contribution of MS plaques to disease evolution through a detailed analysis of individual lesion patterns. 5 This approach allowed to unveil heterogeneous patterns of innate immune cell activation in white matter lesions 6 and to demonstrate that a large percentage of lesions characterized by chronic immune cell activation are detected by TSPO PET but remain completely invisible to post-gadolinium T1 spin-echo MRI sequences (unpublished data from our group). These latter findings clearly point out that the use of PET is essential for a deep phenotyping of brain pathology in MS patients, which is not possible with MRI. Novel PET tracers are currently being developed to distinguish proinflammatory from protective innate immune cells. 7 The future use of these tracers in clinical studies on patients with MS could provide long-awaited answers to key questions on the impact of microglial phenotypes on the development of tissue damage and repair over the course of the disease. Offering the opportunity to identify patient-specific profiles of innate immune cell activation, PET has the potential to become a precious tool to understand the role played by innate immunity in the pathophysiology of disability progression in MS. 
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A second key application of PET in MS research is the quantification of demyelination and remyelination, which is now possible using benzothiazole-and stilbene-derived radiotracers. 5 We now know that each patient with MS is characterized by a specific remyelination profile, which reflects the individual level of spontaneous myelin repair in response to a demyelinating insult and is critical to determine disease evolution and disability. 8 In the next future, the application of myelin-specific fluorinated compounds will allow a wider use of PET in the context of clinical trials evaluating the efficacy of drugs designed to promote myelin repair. Moreover, large longitudinal studies with myelin PET will clarify whether and in which time window myelin repair can be effective in preventing neurodegeneration in each form of disease. Providing a gold standard measure of myelin in vivo, PET will also be essential for the development of optimized MRI tools aiming to specifically quantify myelin content changes in patients with MS.
The investigation of early neuronal damage in MS also benefits from the use of PET tracers selectively directed against neuronal components. Early signs of neurodegeneration in the cortical and deep grey matter have been demonstrated using PET with 11 C-Flumazenil, an antagonist of benzodiazepine sites included in the GABA-A receptor, with a selective neuronal expression on axo-somatic and axodendritic synapses. 9 Novel tracers specifically designed to detect the earliest signs of neuronal stress and dysfunction, such as those targeting the synaptic vesicle glycoprotein 2A, 10 will open new perspectives on the pathophysiology of neurodegeneration in MS.
In the light of the results obtained over recent years, and of the research perspectives opened by the development of new radiotracers, the use of PET will allow to bridge a critical gap between neuropathology and clinical studies in MS research, offering key insights into the mechanisms underlying the disease. Ultimately, longitudinal studies using PET with multiple radiotracers, especially if combined with advanced MRI in the context of hybrid PET/MR systems, will offer the unique opportunity to reconstruct the chronology of pathological events as they unfold over time in living patients, taking to the next level the investigation of the pathophysiology of MS.
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